FI117436B - Förfarande för racemisering av en optiskt anrikad form av levobupivacain och analoger därav - Google Patents

Förfarande för racemisering av en optiskt anrikad form av levobupivacain och analoger därav Download PDF

Info

Publication number
FI117436B
FI117436B FI971202A FI971202A FI117436B FI 117436 B FI117436 B FI 117436B FI 971202 A FI971202 A FI 971202A FI 971202 A FI971202 A FI 971202A FI 117436 B FI117436 B FI 117436B
Authority
FI
Finland
Prior art keywords
acid
compound
racemization
optically enriched
pct
Prior art date
Application number
FI971202A
Other languages
English (en)
Finnish (fi)
Other versions
FI971202A (sv
FI971202A0 (sv
Inventor
Ulrich Conrad Dyer
Martin Woods
Christopher James Lock
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9504927.6A external-priority patent/GB9504927D0/en
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Publication of FI971202A publication Critical patent/FI971202A/sv
Publication of FI971202A0 publication Critical patent/FI971202A0/sv
Application granted granted Critical
Publication of FI117436B publication Critical patent/FI117436B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B53/00—Asymmetric syntheses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B55/00—Racemisation; Complete or partial inversion

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measurement Of Radiation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Claims (5)

1. Förfarande för racemicering av en optiskt anrikad : " förening med formeln (1) ^ CH3 ^ ; CV^ ^
5 CHa j där R1 är metyl, n-propyl, n-butyl eller cyklopropyl, i kännetecknat av att föreningen upphettas i närvaro av ·"; en syra, som har formeln R3COOH, där R3 är n-alkyl eller aryl, och syran har ett pKa-värde inom omrädet av -1 - +6 f 10. förhällande till vatten.
2. Förf arande enligt patentkrav 1, kännetecknat av att racemiseringen utförs i en lösning, som gjorts i enbart syran eller i en blandning av denna med ett inert hjälplösningsmedel. / 15 3. Förfarande enligt patentkrav 1 eller 2, kän netecknat av att föreningen är bupivakain, dvs. en förening med formeln (1), där R1 är n-butyl.
4. Förfarande enligt patentkrav 3, kännetecknat • · ·.1·: av att bupivakainet är anrikat i förhällande till (R) - * « ♦ I I 20 enantiomeren. 1' • · 1
5. Förfarande enligt patentkrav 3 eller 4, kän- • f .r ·;·1· netecknat av att det optiskt anrikade bupivakainet ‘7 i1. upphettas i propansyra eller butansyra. • 1 Φ • · · • ’ 1 ··· ··· * 1 1 • · · ·1'.. ···''1 * 1 · ... • · · • · · • ♦ • 1 • · • · · · · • · * 1 1 » ··1··' * 1 ' · >
FI971202A 1994-09-23 1997-03-21 Förfarande för racemisering av en optiskt anrikad form av levobupivacain och analoger därav FI117436B (sv)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP94306962 1994-09-23
EP94306962 1994-09-23
GB9504927 1995-03-10
GBGB9504927.6A GB9504927D0 (en) 1995-03-10 1995-03-10 Racemisation and asymmetric transformation
PCT/GB1995/002247 WO1996009290A1 (en) 1994-09-23 1995-09-22 Racemisation and asymmetric transformation processes used in the manufacture of levobupivacaine and analogues thereof
GB9502247 1995-09-22

Publications (3)

Publication Number Publication Date
FI971202A FI971202A (sv) 1997-03-21
FI971202A0 FI971202A0 (sv) 1997-03-21
FI117436B true FI117436B (sv) 2006-10-13

Family

ID=26137306

Family Applications (1)

Application Number Title Priority Date Filing Date
FI971202A FI117436B (sv) 1994-09-23 1997-03-21 Förfarande för racemisering av en optiskt anrikad form av levobupivacain och analoger därav

Country Status (18)

Country Link
US (1) US5786484A (sv)
EP (1) EP0782569B1 (sv)
JP (1) JP3898220B2 (sv)
KR (1) KR100393133B1 (sv)
CN (1) CN1104416C (sv)
AT (1) ATE214695T1 (sv)
AU (1) AU695479B2 (sv)
CA (1) CA2200490C (sv)
DE (1) DE69525950T2 (sv)
DK (1) DK0782569T3 (sv)
ES (1) ES2173194T3 (sv)
FI (1) FI117436B (sv)
HU (1) HU216291B (sv)
MX (1) MX9702210A (sv)
NO (1) NO308074B1 (sv)
PL (1) PL183204B1 (sv)
PT (1) PT782569E (sv)
WO (1) WO1996009290A1 (sv)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6384227B2 (en) 1995-01-18 2002-05-07 Darwin Discovery Ltd. Racemisation process for use in the manufacture of levobupivacaine and related piperidinecarboxanilide anaesthetic agents
JP2000256359A (ja) * 1999-03-11 2000-09-19 Japan Science & Technology Corp 面性キラリティーを有する分子群の高選択的不斉変換法
US6288280B1 (en) * 1999-07-09 2001-09-11 Hoffmann-La Roche Inc. Racemization of atropisomeric bis(phosphine oxide) compounds
BR0002246A (pt) 2000-04-06 2003-04-15 Cristalia Prod Quimicos Farm Processo de obtenção dos enantiÈmeros da bupivacaìna racêmica, processo de obtenção de composições farmacêuticas a base de levobupivacaìna: composições farmacêuticas a base de levobupivacaìna formuladas nas formas básicas ou sais farmaceuticamente aceitáveis e utilização das composições farmacêuticas a base de levobupivacaìna formuladas nas formas básicas ou sais farmaceuticamente aceitáveis
EP1295873A4 (en) * 2000-06-14 2004-05-19 METHODS OF PRODUCING RACEMIC PIPERIDINE DERIVATIVE AND PRODUCING OPTICALLY ACTIVE PIPERIDINE DERIVATIVE
US6495694B2 (en) 2000-06-16 2002-12-17 Boehringer Ingelheim Pharma Kg Efficient separation of enantiomers of piperidone derivatives by precipitation of the desired eantiomer during in situ racemization of the unwanted enantiomer
DE10029851A1 (de) * 2000-06-16 2001-12-20 Boehringer Ingelheim Pharma Enantiomerentrennung von Piperidon-Derivaten unter gleichzeitiger in situ Racemisierung des unerwünschten Enantiomers
BRPI0104491B8 (pt) * 2001-10-10 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda n-(2,6-dimetilfenil)-1-propil-2-piperidinocarboxamida; processo de obtenção dos enantiômeros; mistura não racêmica dos anantiômeros e seu processo de obtenção e composição farmacêutica.
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
ATE482695T1 (de) 2002-12-13 2010-10-15 Durect Corp Orale darreichungsform mit flüssigen hochviskosen trägersystemen
LT2767292T (lt) * 2004-09-17 2016-12-12 Durect Corporation Palaikomosios vietinės anestezijos mišinys su saib
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
DK2117521T3 (da) 2006-11-03 2012-09-03 Durect Corp Transdermale indgivelsessystemer omfattende bupivacain
AU2008335809A1 (en) * 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
CN102093284B (zh) * 2010-12-29 2013-05-08 宜昌人福药业有限责任公司 富集哌啶-2-甲酰苯胺类旋光化合物的方法
TW201521769A (zh) 2013-03-15 2015-06-16 Durect Corp 具有流變改質劑以減少溶解變異性之組成物
CN103664744B (zh) * 2013-11-30 2015-07-15 山东永泰化工有限公司 一种左布比卡因的制备方法
WO2019222565A1 (en) * 2018-05-18 2019-11-21 Kura Oncology, Inc. Synthesis of tipifarnib
BR112022013784A2 (pt) 2020-01-13 2022-10-11 Durect Corp Sistemas de distribuição de fármacos de liberação prolongada com impurezas reduzidas e métodos relacionados

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE451840B (sv) * 1986-01-03 1987-11-02 Astra Laekemedel Ab Optiskt rent monohydrat av s-(-)-1-propyl-2',6'-pipekoloxylididhydroklorid, sett att framstella denna och farmaceutiska beredningar for lokalbedovning

Also Published As

Publication number Publication date
CA2200490C (en) 2007-01-09
HUT77055A (hu) 1998-03-02
NO971358D0 (no) 1997-03-21
PL183204B1 (pl) 2002-06-28
PT782569E (pt) 2002-09-30
CN1159184A (zh) 1997-09-10
US5786484A (en) 1998-07-28
KR100393133B1 (ko) 2003-11-17
ES2173194T3 (es) 2002-10-16
AU695479B2 (en) 1998-08-13
CN1104416C (zh) 2003-04-02
ATE214695T1 (de) 2002-04-15
HU216291B (hu) 1999-06-28
FI971202A (sv) 1997-03-21
DK0782569T3 (da) 2002-07-22
CA2200490A1 (en) 1996-03-28
FI971202A0 (sv) 1997-03-21
AU3527995A (en) 1996-04-09
EP0782569B1 (en) 2002-03-20
DE69525950T2 (de) 2002-09-19
DE69525950D1 (de) 2002-04-25
EP0782569A1 (en) 1997-07-09
PL319368A1 (en) 1997-08-04
NO308074B1 (no) 2000-07-17
JP3898220B2 (ja) 2007-03-28
NO971358L (no) 1997-03-21
WO1996009290A1 (en) 1996-03-28
JPH10505855A (ja) 1998-06-09
MX9702210A (es) 1998-05-31

Similar Documents

Publication Publication Date Title
FI117436B (sv) Förfarande för racemisering av en optiskt anrikad form av levobupivacain och analoger därav
JP7030208B2 (ja) Ｏ，ｏ’－二置換酒石酸エナンチオマーの添加によるラセミ体ニコチンのエナンチオマー分離
ATE515496T1 (de) Verfahren zur herstellung von enantiomerenangereicherter indolin-2-carbonsäure
FI117438B (sv) Förfarande för framställning av optiskt anrikat bupivakain
DE69623900D1 (de) Verfahren zur Herstellung von enantiomerisch reinen Imidazol-Verbindungen
JP4015696B2 (ja) レボブピバカインと同類のピペリジンカルボキサニリド麻酔剤の製造に用いるラセミ化法
JP2000504684A (ja) 第４級キラル中心のラセミ化
WO2006059347A2 (en) Improved process for preparation of ramipril
JPH10507173A (ja) レボブピバカインとその類似体のｌ−リシンからの製造法
KR20090023603A (ko) 네포팜과 유사체의 거울상 이성질체의 라세미화
JPH11510471A (ja) レボブピバカインおよびその前駆体のラセミ化法

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 117436

Country of ref document: FI

MA Patent expired